JP7204005B2 - タンパク質チロシンホスファターゼ阻害物質及びその使用方法 - Google Patents

タンパク質チロシンホスファターゼ阻害物質及びその使用方法 Download PDF

Info

Publication number
JP7204005B2
JP7204005B2 JP2021555178A JP2021555178A JP7204005B2 JP 7204005 B2 JP7204005 B2 JP 7204005B2 JP 2021555178 A JP2021555178 A JP 2021555178A JP 2021555178 A JP2021555178 A JP 2021555178A JP 7204005 B2 JP7204005 B2 JP 7204005B2
Authority
JP
Japan
Prior art keywords
alkyl
hydroxy
fluoro
trione
thiadiazolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021555178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522526A (ja
Inventor
アンドリュー ボグダン
ジェフ ティー． ハルボーセン
エリオット ピー． ファーニー
ジェニファー エム． フロスト
フィリップ アール． キム
マーク エイ． マトゥレンコ
マシュー オコナー
レザ シルーディ
エリック ヴォイト
チャオミン ション
シンウェイ チャン
クリスティーナ バウムガートナー
ジェイソン アボット
クリストス エコノモウ
ステイシー フォス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2022522526A publication Critical patent/JP2022522526A/ja
Priority to JP2022209142A priority Critical patent/JP7617890B2/ja
Application granted granted Critical
Publication of JP7204005B2 publication Critical patent/JP7204005B2/ja
Priority to JP2025002163A priority patent/JP2025061064A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Oncology (AREA)
JP2021555178A 2019-03-14 2020-03-13 タンパク質チロシンホスファターゼ阻害物質及びその使用方法 Active JP7204005B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022209142A JP7617890B2 (ja) 2019-03-14 2022-12-27 タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP2025002163A JP2025061064A (ja) 2019-03-14 2025-01-07 タンパク質チロシンホスファターゼ阻害物質及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962818447P 2019-03-14 2019-03-14
US62/818,447 2019-03-14
PCT/US2020/022717 WO2020186199A1 (en) 2019-03-14 2020-03-13 Protein tyrosine phosphatase inhibitors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022209142A Division JP7617890B2 (ja) 2019-03-14 2022-12-27 タンパク質チロシンホスファターゼ阻害物質及びその使用方法

Publications (2)

Publication Number Publication Date
JP2022522526A JP2022522526A (ja) 2022-04-19
JP7204005B2 true JP7204005B2 (ja) 2023-01-13

Family

ID=70190226

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021555178A Active JP7204005B2 (ja) 2019-03-14 2020-03-13 タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP2022209142A Active JP7617890B2 (ja) 2019-03-14 2022-12-27 タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP2025002163A Pending JP2025061064A (ja) 2019-03-14 2025-01-07 タンパク質チロシンホスファターゼ阻害物質及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022209142A Active JP7617890B2 (ja) 2019-03-14 2022-12-27 タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP2025002163A Pending JP2025061064A (ja) 2019-03-14 2025-01-07 タンパク質チロシンホスファターゼ阻害物質及びその使用方法

Country Status (24)

Country Link
US (1) US10851073B2 (enExample)
EP (1) EP3938038A1 (enExample)
JP (3) JP7204005B2 (enExample)
KR (3) KR102983496B1 (enExample)
CN (2) CN116332873A (enExample)
AR (1) AR118374A1 (enExample)
AU (2) AU2020234712B2 (enExample)
BR (1) BR112021017430A2 (enExample)
CA (1) CA3131894A1 (enExample)
CL (2) CL2021002382A1 (enExample)
CO (1) CO2021013524A2 (enExample)
CR (1) CR20210516A (enExample)
DO (1) DOP2021000188A (enExample)
EC (1) ECSP21075909A (enExample)
IL (2) IL286373B2 (enExample)
MA (1) MA55301A (enExample)
MX (2) MX2024010859A (enExample)
MY (1) MY209419A (enExample)
PE (2) PE20252767A1 (enExample)
PH (1) PH12021552194A1 (enExample)
SG (1) SG11202109067PA (enExample)
TW (2) TWI849082B (enExample)
UY (1) UY38613A (enExample)
WO (1) WO2020186199A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023052094A (ja) * 2019-03-14 2023-04-11 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP2023542503A (ja) * 2020-09-11 2023-10-10 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020401376A1 (en) 2019-12-12 2022-06-30 Kumquat Biosciences Inc. Compositions and methods for potentiating immune activity
MX2022007441A (es) * 2019-12-18 2022-09-02 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
IL305072A (en) * 2021-02-12 2023-10-01 Recovery Therapeutics Inc Compounds, compositions, and methods for modulating fgf activity
EP4305030A4 (en) * 2021-03-11 2025-05-21 Kumquat Biosciences Inc. HETEROCYCLES AND THEIR USES
EP4351558A4 (en) * 2021-06-10 2025-05-07 Ness Therapeutics, Inc. Compounds containing 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes
CN118556055A (zh) * 2021-11-11 2024-08-27 卡里科生命科学有限责任公司 蛋白酪氨酸磷酸酶抑制剂及其使用方法
MX2024005658A (es) * 2021-11-11 2024-08-06 Calico Life Sciences Llc Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos.
CN119137117A (zh) * 2022-02-02 2024-12-13 耐瑞欧医疗公司 蛋白酪氨酸磷酸酶抑制剂及其用途
IL314650A (en) * 2022-02-02 2024-09-01 Nerio Therapeutics Inc Protein tyrosine phosphatase inhibitors and uses thereof
EP4472957A4 (en) * 2022-02-02 2026-04-15 Nerio Therapeutics Inc TYROSINE PHOSPHATASE PROTEIN INHIBITORS AND THEIR USES
JP2025510741A (ja) * 2022-03-21 2025-04-15 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
WO2023200964A1 (en) * 2022-04-14 2023-10-19 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
KR20250011138A (ko) * 2022-05-13 2025-01-21 네스 테라퓨틱스 인코포레이티드 Ptpn2 저해제
JP2025530135A (ja) * 2022-09-13 2025-09-11 カムクワット バイオサイエンシーズ インコーポレイテッド ベンゾ縮合ｎ－複素環及びその使用
WO2024067802A1 (zh) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
WO2024141015A1 (en) * 2022-12-30 2024-07-04 Insilico Medicine Ip Limited Protein tyrosine phosphatase inhibitors and uses thereof
WO2024243441A1 (en) * 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
JP2026525318A (ja) * 2023-07-11 2026-07-29 シェンチェン チョンコー バイオロジカル テクノロジー カンパニー リミテッド タンパク質チロシンホスファターゼ阻害剤、それを含む組成物、及びその医学的使用
TW202519514A (zh) 2023-07-14 2025-05-16 天主教魯汶大學 新穎化合物(一)
CN121487923A (zh) * 2023-07-28 2026-02-06 杭州中美华东制药有限公司 具有ptpn2抑制作用的化合物及其用途
WO2025030008A1 (en) * 2023-08-02 2025-02-06 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitor combinations
WO2025055985A1 (zh) * 2023-09-15 2025-03-20 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
CN120004876B (zh) * 2023-11-16 2026-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
WO2025136841A1 (en) * 2023-12-19 2025-06-26 Merck Sharp & Dohme Llc Substituted isoquinoline derivatives and methods of use thereof
WO2025242216A1 (zh) * 2024-05-24 2025-11-27 杭州百新生物医药科技有限公司 吲哚啉类化合物及其用途
WO2026077417A1 (zh) * 2024-10-11 2026-04-16 杭州百新生物医药科技有限公司 一种用于制备ptpn1/n2抑制剂的中间体及其制备方法和用途
WO2026108900A1 (zh) * 2024-11-20 2026-05-28 湖北生物医药产业技术研究院有限公司 作为蛋白质酪氨酸磷酸酶抑制剂的含苯并环类化合物及其用途
WO2026112350A1 (en) * 2024-11-22 2026-05-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2026132146A1 (en) 2024-12-19 2026-06-25 Katholieke Universiteit Leuven Inhibitors of ptpn 2/ ptpn1 tyrosine phosphatase
WO2026132148A1 (en) 2024-12-19 2026-06-25 Katholieke Universiteit Leuven Inhibitors of ptpn2/ptpn1 tyrosine phosphatase
WO2026132149A1 (en) 2024-12-19 2026-06-25 Katholieke Universiteit Leuven Inhibitors of ptpn2 and/or ptpn1
WO2026132150A1 (en) 2024-12-19 2026-06-25 Katholieke Universiteit Leuven Inhibitors of ptpn 2/ ptpn1 tyrosine phosphatase
WO2026130528A1 (zh) * 2024-12-20 2026-06-25 杭州百新生物医药科技有限公司 Ptpn2/ptpn1抑制剂及其制备方法和医药用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518419A (ja) 2005-12-08 2009-05-07 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅ阻害剤としての１−オルトフルオロフェニル置換１，２，５−チアゾリジンジオン誘導体
JP2009532379A (ja) 2006-03-31 2009-09-10 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅのチアジアゾリジノン阻害剤
JP2010529075A (ja) 2007-06-04 2010-08-26 ノバルティス アーゲー 抗糖尿病剤としてのチアジアゾール誘導体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
EP1439834A1 (en) 2001-10-30 2004-07-28 Applied Research Systems ARS Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
UA94724C2 (en) 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
WO2008142198A2 (en) 2007-05-23 2008-11-27 Valtion Teknillinen Tutkimuskeskus A method for inhibiting or stimulating angiogenesis in an individual
WO2010008852A2 (en) 2008-06-23 2010-01-21 Taiga Biotechnologies, Inc. Methods of trea fing λλd methods of diagnosing an immunoproliferative disorder
US9217012B2 (en) 2009-04-08 2015-12-22 Indiana University Research And Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2011057331A1 (en) 2009-11-11 2011-05-19 Monash University A method for treating obesity
EP2531616A4 (en) 2010-02-03 2013-07-10 Univ Monash DIAGNOSIS AND FORECAST ASSAY FOR BREAST CANCER
US20150291554A1 (en) * 2012-11-02 2015-10-15 Pfizer Inc. Bruton's Tyrosine Kinase Inhibitors
CA2977839C (en) 2014-02-28 2022-07-26 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
JP2017524348A (ja) 2014-06-10 2017-08-31 モナッシュ ユニバーシティ 養子細胞移入のためのｐｔｐｎ２阻害を用いた白血球の産生方法
WO2016050921A1 (en) * 2014-10-02 2016-04-07 F. Hoffmann-La Roche Ag Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk)
WO2017078499A2 (ko) 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
KR101826690B1 (ko) 2015-11-06 2018-03-22 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
WO2018148378A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
WO2018227248A1 (en) 2017-06-13 2018-12-20 Monash University Methods and compositions for the treatment of obesity
WO2019036815A1 (en) 2017-08-24 2019-02-28 The Royal Institution For The Advancement Of Learning/Mcgill University ENHANCEMENT OF CD8 + T LYMPHOCYTES FOR ADOPTIVE CELL THERAPY BY INHIBITING PTPN1 (PTP1B) AND PTPN2 (TC-PTP))
TWI888352B (zh) 2018-06-21 2025-07-01 美商嘉來克生命科學有限責任公司 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法
KR102983496B1 (ko) * 2019-03-14 2026-06-29 칼리코 라이프 사이언시스 엘엘씨 단백질 티로신 포스파타제 억제제 및 이의 사용 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518419A (ja) 2005-12-08 2009-05-07 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅ阻害剤としての１−オルトフルオロフェニル置換１，２，５−チアゾリジンジオン誘導体
JP2009532379A (ja) 2006-03-31 2009-09-10 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅのチアジアゾリジノン阻害剤
JP2010529075A (ja) 2007-06-04 2010-08-26 ノバルティス アーゲー 抗糖尿病剤としてのチアジアゾール誘導体

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023052094A (ja) * 2019-03-14 2023-04-11 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP7617890B2 (ja) 2019-03-14 2025-01-20 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP2025061064A (ja) * 2019-03-14 2025-04-10 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
JP2023542503A (ja) * 2020-09-11 2023-10-10 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法

Also Published As

Publication number Publication date
KR20230074822A (ko) 2023-05-31
AU2020234712A1 (en) 2021-09-09
CL2024001723A1 (es) 2024-11-22
AU2020234712B2 (en) 2025-12-04
CL2021002382A1 (es) 2022-06-03
KR102533599B1 (ko) 2023-05-17
DOP2021000188A (es) 2022-03-15
WO2020186199A1 (en) 2020-09-17
CN114025844B (zh) 2022-07-26
MA55301A (fr) 2022-01-19
US10851073B2 (en) 2020-12-01
TWI849082B (zh) 2024-07-21
CN116332873A (zh) 2023-06-27
MX2024010859A (es) 2024-09-11
IL286373B2 (en) 2026-03-01
IL324019A (en) 2025-12-01
CA3131894A1 (en) 2020-09-17
MY209419A (en) 2025-07-08
TW202100515A (zh) 2021-01-01
KR20260110254A (ko) 2026-07-14
PH12021552194A1 (en) 2022-08-22
AR118374A1 (es) 2021-09-29
BR112021017430A2 (pt) 2022-01-18
EP3938038A1 (en) 2022-01-19
JP2025061064A (ja) 2025-04-10
JP2023052094A (ja) 2023-04-11
AU2026201609A1 (en) 2026-03-26
PE20212154A1 (es) 2021-11-09
TW202519515A (zh) 2025-05-16
CN114025844A (zh) 2022-02-08
IL286373B1 (en) 2025-11-01
US20200299246A1 (en) 2020-09-24
MX2021010544A (es) 2021-10-01
SG11202109067PA (en) 2021-09-29
JP2022522526A (ja) 2022-04-19
CO2021013524A2 (es) 2022-02-28
KR102983496B1 (ko) 2026-06-29
JP7617890B2 (ja) 2025-01-20
UY38613A (es) 2020-09-30
CR20210516A (es) 2022-07-19
IL286373A (en) 2021-10-31
PE20252767A1 (es) 2025-12-22
ECSP21075909A (es) 2021-11-30
KR20210151821A (ko) 2021-12-14

Similar Documents

Publication Publication Date Title
JP7617890B2 (ja) タンパク質チロシンホスファターゼ阻害物質及びその使用方法
AU2023263567B2 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
JP7751582B2 (ja) タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
JP2023542503A (ja) タンパク質チロシンホスファターゼ阻害物質及びその使用方法
RU2833220C2 (ru) Ингибиторы белковых тирозинфосфатаз и способы их применения
RU2799446C2 (ru) Ингибиторы протеин-тирозинфосфатазы и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220325

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221227

R150 Certificate of patent or registration of utility model

Ref document number: 7204005

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250